Mylan Receives New Coverage from Analysts at RBC Capital (MYL)
Stock analysts at RBC Capital initiated coverage on shares of Mylan (NASDAQ:MYL) in a report issued on Tuesday, Analyst RN reports. The firm set an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on MYL. Analysts at BMO Capital Markets raised their price target on shares of Mylan from $25.00 to $30.00 in a research note to investors on Tuesday, November 5th. They now have an “underperform” rating on the stock. Separately, analysts at Citigroup Inc. initiated coverage on shares of Mylan in a research note to investors on Friday, October 25th. They set a “neutral” rating and a $42.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Mylan from $39.00 to $46.00 in a research note to investors on Tuesday, October 15th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.50.
Mylan (NASDAQ:MYL) traded up 1.70% on Tuesday, hitting $42.98. 3,109,074 shares of the company’s stock traded hands. Mylan has a 52 week low of $27.38 and a 52 week high of $44.73. The stock has a 50-day moving average of $42.84 and a 200-day moving average of $37.91. The company has a market cap of $16.455 billion and a P/E ratio of 27.78.
Mylan, Inc develops and markets generics along with a number of proprietary drugs. The Company’s product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson’s disease, and a wound care product to treat diabetic foot ulcers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.